Clinical trial evaluation: the EDOSURE clinical trial program.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Direct oral anticoagulants (DOACs) offer alternatives to traditional therapies.
• Edoxaban is a DOAC evaluated for various thromboembolic conditions.
• The EDOSURE program consolidated evidence on edoxaban's efficacy and safety.

Purpose of the Study:

• To review the context, rationale, and key findings of the EDOSURE trial program.
• To summarize evidence supporting edoxaban use in nonvalvular atrial fibrillation and venous thromboembolism.
• To highlight edoxaban's role in special patient populations and its guideline recommendations.

Main Methods:

• The EDOSURE program comprised ten randomized clinical trials.
• Eight trials have been published, evaluating edoxaban across different indications.
• Studies included patients with nonvalvular atrial fibrillation, venous thromboembolism, and specific clinical scenarios.

Main Results:

• Edoxaban demonstrated efficacy in treating nonvalvular atrial fibrillation and venous thromboembolism.
• The drug showed utility in special circumstances, including cardiac procedures and cancer-associated VTE.
• Evidence supported edoxaban use in elderly patients with high bleeding risk.

Conclusions:

• The collective evidence from EDOSURE supports edoxaban as a recommended treatment option.
• International guidelines now include edoxaban for anticoagulation.
• Edoxaban provides a valuable therapeutic option for diverse patient groups requiring anticoagulation.